Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer
作者： Robert Pirker
DOI: 10.3978/J.ISSN.2218-6751.2014.09.13
关键词: Vinorelbine 、 Bioinformatics 、 Adjuvant therapy 、 Immunotherapy 、 Lung cancer 、 Internal medicine 、 Medicine 、 Oncology 、 Adjuvant 、 non-small cell lung cancer (NSCLC) 、 Cisplatin 、 Chemotherapy
摘要: Adjuvant chemotherapy has been established as a standard for patients with completely resected non-small cell lung cancer (NSCLC). increased the 5-year survival rates by 4% to 15% within randomized trials and, based on meta-analysis of five cisplatin-based trials, 5.4%. consists doublet, preferentially cisplatin plus vinorelbine. Future improvements in outcome adjuvant therapy are expected customized and integration targeted therapies or immunotherapy.
amegroups.com参考文章(29)
Jean-Yves Douillard, Hélène Tribodet, Delphine Aubert, Frances A. Shepherd, Rafael Rosell, Keyue Ding, Anne-Sophie Veillard, Lesley Seymour, Thierry Le Chevalier, Stephen Spiro, Richard Stephens, Jean Pierre Pignon, Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation Journal of Thoracic Oncology. ,vol. 5, pp. 220- 228 ,(2010) , 10.1097/JTO.0B013E3181C814E7
Martin Filipits, Vincent Haddad, Katharina Schmid, Anh Huynh, Ariane Dunant, Fabrice André, Elisabeth Brambilla, Rolf Stahel, Jean-Pierre Pignon, Jean-Charles Soria, Helmut H Popper, Thierry Le Chevalier, Robert Pirker, None, Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non–Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program Clinical Cancer Research. ,vol. 13, pp. 3892- 3898 ,(2007) , 10.1158/1078-0432.CCR-06-2446
Leora Horn, Alan B Sandler, Joe B Putnam Jr, David H Johnson, None, The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer. Journal of Thoracic Oncology. ,vol. 2, pp. 377- 383 ,(2007) , 10.1097/01.JTO.0000268669.64625.BB
Natasha B. Leighl, Raymond Ng, Baktiar Hasan, Nicole Mittmann, Marie Florescu, Frances A. Shepherd, Keyue Ding, Charles Andrew Butts, Yvon Cormier, Gail Darling, Glenwood D. Goss, Richard Inculet, Lesley Seymour, Timothy L. Winton, William K. Evans, Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non–Small-Cell Lung Cancer—A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group Journal of Clinical Oncology. ,vol. 25, pp. 2256- 2261 ,(2007) , 10.1200/JCO.2006.09.4342
Ken A Olaussen, Ariane Dunant, Pierre Fouret, Elisabeth Brambilla, Fabrice André, Vincent Haddad, Estelle Taranchon, Martin Filipits, Robert Pirker, Helmut H Popper, Rolf Stahel, Laure Sabatier, Jean-Pierre Pignon, Thomas Tursz, Thierry Le Chevalier, Jean-Charles Soria, None, DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. The New England Journal of Medicine. ,vol. 355, pp. 983- 991 ,(2006) , 10.1056/NEJMOA060570
Luc Friboulet, Ken André Olaussen, Jean-Pierre Pignon, Frances A Shepherd, Ming-Sound Tsao, Stephen Graziano, Robert Kratzke, Jean-Yves Douillard, Lesley Seymour, Robert Pirker, Martin Filipits, Fabrice André, Eric Solary, Florence Ponsonnailles, Angélique Robin, Annabelle Stoclin, Nicolas Dorvault, Frédéric Commo, Julien Adam, Elsa Vanhecke, Patrick Saulnier, Jürgen Thomale, Thierry Le Chevalier, Ariane Dunant, Vanessa Rousseau, Gwénaël Le Teuff, Elisabeth Brambilla, Jean-Charles Soria, None, ERCC1 Isoform Expression and DNA Repair in Non-Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 368, pp. 1101- 1110 ,(2013) , 10.1056/NEJMOA1214271
Johan Vansteenkiste, Marcin Zielinski, Albert Linder, Jubrail Dahabreh, Emilio E. Gonzalez, Wojciech Malinowski, Marta Lopez-Brea, Tonu Vanakesa, Jacek Jassem, Haralabos Kalofonos, Jakub Perdeus, Reiner Bonnet, Jazeps Basko, Richard Janilionis, Bernward Passlick, Tom Treasure, Marc Gillet, Frédéric F. Lehmann, Vincent G. Brichard, Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results Journal of Clinical Oncology. ,vol. 31, pp. 2396- 2403 ,(2013) , 10.1200/JCO.2012.43.7103
Naveed Alam, Frances A. Shepherd, Timothy Winton, Barbara Graham, David Johnson, Robert Livingston, James Rigas, Marlo Whitehead, Keyue Ding, Lesley Seymour, Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer an analysis of National Cancer Institute of Canada and intergroup trial JBR. 10 and a review of the literature Lung Cancer. ,vol. 47, pp. 385- 394 ,(2005) , 10.1016/J.LUNGCAN.2004.08.016
I. Gauthier, K. Ding, T. Winton, F.A. Shepherd, R. Livingston, D.H. Johnson, J.R. Rigas, M. Whitehead, B. Graham, L. Seymour, Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience. Lung Cancer. ,vol. 55, pp. 357- 363 ,(2007) , 10.1016/J.LUNGCAN.2006.10.021
D WALLER, M PEAKE, R STEPHENS, N GOWER, R MILROY, M PARMAR, R RUDD, S SPIRO, ONBEHALFOFALLBLTPARTICIPANTS, Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. European Journal of Cardio-Thoracic Surgery. ,vol. 26, pp. 173- 182 ,(2004) , 10.1016/J.EJCTS.2004.03.041